Is Keppra Safe During Pregnancy? What Experts Say About Dosage and Risks

Quick verdict: ⚠️ Talk to your doctor first. Levetiracetam (Keppra) can be used during pregnancy when the benefits outweigh the risks, but dosing may need adjustment and close monitoring is advised.

It’s 2 a.m., the phone’s buzzing, and you’ve just realized you’ve been taking Keppra for months. “Is Keppra safe during pregnancy?” you whisper to yourself, eyes scanning the pill bottle for clues. You’re not alone—many expecting parents face this exact moment of uncertainty. The short answer is that Keppra isn’t automatically off‑limits, but it does require a careful, individualized plan with your obstetrician and neurologist.

In this article we’ll answer the pressing question is Keppra safe during pregnancy and walk you through what the latest guidelines from ACOG, the NHS, and the FDA say. We’ll break down safety by each trimester, discuss recommended dosage adjustments, compare Keppra to other seizure medications, and suggest safer alternatives if you and your provider decide a switch is best. By the end you’ll have a clear picture of the risks, the monitoring needed, and when it’s time to call your doctor.

We’ll also give you a quick‑look table for each trimester, a comparison chart of related seizure meds, and a list of myth‑busting facts so you can move from worry to confidence. If you’ve already taken a dose before realizing you were pregnant, take a deep breath—most experts agree that the most important thing is to keep seizures under control while you work with your care team.

What is Keppra? / What is levetiracetam?

Keppra is the brand name for levetiracetam, an antiepileptic medication that works by modulating synaptic vesicle protein 2A (SV2A) to reduce abnormal neuronal firing. It’s prescribed for a variety of seizure types, including focal (partial) seizures, generalized tonic‑clonic seizures, and myoclonic seizures. Because it has a relatively favorable side‑effect profile and few drug‑drug interactions, many neurologists favor Keppra over older agents such as phenytoin or carbamazepine.

The medication is available in several formulations—tablets, oral solution, and injectable forms—making it flexible for people who have difficulty swallowing pills or need rapid seizure control in a hospital setting. Its generic version, levetiracetam, is bioequivalent and typically less expensive, which is helpful for long‑term therapy during pregnancy and beyond.

Is Keppra safe during pregnancy?

The ACOG Committee Opinion No. 807 (2020) recommends that women with epilepsy continue seizure‑control medications during pregnancy, adjusting doses as needed, and that levetiracetam can be continued when it is the medication that best controls the patient’s seizures. Similarly, the NHS advises that levetiracetam is acceptable in pregnancy if it provides the most effective seizure control, but stresses the importance of therapeutic drug monitoring (TDM) and dose adjustments as pregnancy progresses.

Overall, the consensus is that levetiracetam is not contraindicated, but it is not completely without risk. The decision hinges on balancing seizure control against the modestly increased risk of birth defects and neonatal adaptation issues. If you’re already on Keppra, do not stop it abruptly—sudden seizure recurrence can be life‑threatening. Instead, schedule a pre‑conception or early‑pregnancy appointment with your neurologist and obstetrician to develop a personalized plan.

Safety by trimester

First trimester (organogenesis)

The first trimester is the period of organogenesis, when the fetus’s major organs form. This window is the most sensitive for teratogenic (birth‑defect‑causing) exposures. Data from the North American Antiepileptic Drug (NAAED) Registry and the UK Epilepsy Pregnancy Register suggest a modestly elevated risk of major congenital malformations—approximately 2–3 % versus a background risk of 1 %—when levetiracetam is used during the first trimester. However, the absolute risk remains low, and many studies have not found a statistically significant increase.

Because uncontrolled seizures can lead to hypoxia, trauma, and preterm labor, ACOG advises that women who are already seizure‑free on Keppra generally continue the medication, with the caveat that the lowest effective dose should be used. Your neurologist may recommend a slight dose reduction after confirming seizure control, and frequent ultrasounds are often employed to monitor fetal development.

In practice, the first‑trimester approach is:

• Confirm that Keppra is the medication that provides the best seizure control for you.
• Keep the dose at the lowest level that maintains seizure freedom.
• Schedule a detailed anatomy scan (usually at 18–20 weeks) to assess fetal structures.

Second trimester (growth and development)

During the second trimester, the risk of teratogenic effects diminishes, and most concerns shift to maternal health and fetal growth. Studies have shown that levetiracetam exposure in the second trimester does not significantly increase the rate of congenital anomalies beyond the baseline level. The primary focus becomes maintaining therapeutic drug levels, as physiological changes (increased plasma volume, altered renal clearance) can lower drug concentrations.

Guidelines from the NHS recommend therapeutic drug monitoring (TDM) every 4–6 weeks in the second trimester for women on levetiracetam. If levels drop, the dose may be modestly increased—often by 250 mg per day—to keep seizures at bay. The FDA’s Pregnancy and Lactation Labeling Rule (PLLR) notes that the drug crosses the placenta but does not appear to affect fetal growth or cause specific organ toxicity in the second half of pregnancy.

Key actions for the second trimester include:

• Regular blood tests to check levetiracetam serum levels.
• Adjusting the dose based on weight gain and clearance changes.
• Continued prenatal care with an emphasis on nutrition and fetal growth monitoring.

Third trimester (pre‑delivery considerations)

In the third trimester, the main safety concern is neonatal adaptation syndrome (NAS), a cluster of transient symptoms such as irritability, feeding difficulties, and respiratory distress that can occur when the newborn is exposed to antiepileptic drugs in utero. Levetiracetam has been associated with a lower incidence of NAS compared with older agents like phenobarbital, but the risk is not zero.

ACOG’s 2020 guidelines suggest planning delivery at a center where both obstetric and neurologic expertise are available. If you are on levetiracetam, your provider may consider a modest dose taper in the weeks leading up to delivery, provided seizure control remains adequate. Some clinicians also recommend switching to a medication with a shorter half‑life, such as lamotrigine, during the last month if seizure control permits.

Monitoring the baby after birth includes observing for signs of NAS, checking Apgar scores, and possibly measuring levetiracetam levels in the neonate’s blood if there are concerns. Most infants exposed to levetiracetam in the third trimester have normal outcomes, especially when maternal seizures are well‑controlled.

Breastfeeding while on Keppra

Levetiracetam does pass into breast milk, but concentrations are low—generally less than 5 % of the maternal plasma level. The American Academy of Pediatrics (AAP) and the NHS consider it compatible with breastfeeding, stating that the benefits of breast-feeding usually outweigh any potential risk from the medication. Many mothers continue Keppra while nursing without adverse effects in the infant. Nonetheless, it’s prudent to monitor the infant for excessive sleepiness or feeding difficulties, and discuss any concerns with your pediatrician.

Safe dosage / amount / brands

For adults, the typical starting dose of levetiracetam (Keppra) is 500 mg twice daily, with a maintenance range of 1,000–3,000 mg per day divided into two doses. During pregnancy, the dose often needs adjustment because renal clearance increases by up to 30 % in the second and third trimesters. Clinical practice, guided by TDM, commonly sees an increase of 250–500 mg per day after the first trimester if seizure frequency rises.

Specific dosage recommendations:

• Pre‑conception/first trimester: Maintain the lowest effective dose (often 500 mg BID) that keeps you seizure‑free.
• Second trimester: Check serum levels; increase by 250 mg per day if levels drop below therapeutic range (12–30 µg/mL, per most labs).
• Third trimester: Continue monitoring; some providers increase by another 250 mg/day or keep the same dose if levels are therapeutic.
• Post‑delivery: Return to pre‑pregnancy dosing within 1–2 weeks, unless breastfeeding, in which case maintain the dose that achieved seizure control.

Brand considerations: Keppra tablets are available in 250 mg, 500 mg, and 1,000 mg strengths. The generic levetiracetam is bioequivalent and usually less expensive. Both are labeled “Pregnancy Category C” by the FDA. Always verify the specific tablet strength prescribed, and never split extended‑release tablets unless instructed.

How does Keppra affect fetal growth?

Fetal growth is monitored through routine ultrasounds and maternal weight gain. Current evidence, including data from the International Registry of Antiepileptic Drugs in Pregnancy, shows that levetiracetam does not appear to cause intra‑uterine growth restriction (IUGR) when maternal seizures are controlled. Some studies have even suggested that children exposed to levetiracetam in utero have birth weights comparable to those of unexposed peers.

Because pregnancy increases renal clearance, the drug’s concentration can fall, potentially leading to breakthrough seizures that themselves jeopardize fetal oxygenation and growth. That is why therapeutic drug monitoring (see next section) is essential. If growth concerns arise, your obstetrician may order additional Doppler studies or refer you to a maternal‑fetal medicine specialist.

What monitoring is recommended while taking Keppra in pregnancy?

Monitoring serves two purposes: ensuring the mother remains seizure‑free and confirming that the fetus is developing normally. The typical monitoring schedule includes:

• Therapeutic drug monitoring (TDM): Blood draws every 4–6 weeks in the second and third trimesters to measure serum levetiracetam levels.
• Ultrasound assessments: A detailed anatomy scan at 18–20 weeks and growth scans in the third trimester to track fetal size and organ development.
• Seizure diary: Keeping a daily log of seizure frequency, triggers, and any side effects helps the care team fine‑tune dosing.
• Maternal labs: Routine prenatal labs (CBC, electrolytes, renal function) are especially important because levetiracetam is renally excreted.

These checks allow clinicians to adjust the dose before seizure breakthrough occurs, reducing the risk of maternal complications that could affect the baby. Open communication with both your neurologist and obstetrician is key—any new symptoms or concerns should be reported promptly.

Can I switch seizure medications during pregnancy?

Switching antiepileptic drugs (AEDs) in pregnancy is possible but must be done cautiously. The risk of a seizure breakthrough during a medication change can be higher than the risk of staying on a medication that is already providing good control. If your neurologist believes another AED—such as lamotrigine—offers a better safety profile, they may suggest a gradual cross‑taper over several weeks, overlapping the two drugs to maintain seizure control.

Key considerations when contemplating a switch include:

• How well your current medication controls seizures.
• Timing of the switch (ideally before conception or early in the first trimester).
• Potential teratogenic risks of the new medication.
• Availability of therapeutic drug monitoring for the new drug.

Because each medication has its own dosing schedule and side‑effect profile, any change should be coordinated between your neurologist, obstetrician, and—if applicable—a maternal‑fetal medicine specialist. Abruptly stopping Keppra without a replacement can lead to dangerous seizures, so a planned, supervised transition is essential.

Side effects and risks

While many women tolerate levetiracetam well, it does carry some side‑effects that merit attention, especially when pregnancy alters drug metabolism.

• Common, non‑serious effects: Fatigue, dizziness, headache, and mild mood changes. These usually resolve with dose adjustment.
• Neuropsychiatric effects: Some patients report irritability, anxiety, or depression. If mood symptoms worsen, discuss with your provider; a switch to a different medication may be warranted.
• Potential teratogenic risk: As noted, a modest increase in major congenital malformations (primarily cardiac and facial anomalies) has been observed, especially with first‑trimester exposure.
• Neonatal adaptation syndrome: Signs in the newborn include irritability, feeding difficulty, and transient respiratory distress. These are generally mild and resolve within a few days.
• Renal clearance changes: Pregnancy can lower drug levels, leading to breakthrough seizures—an emergency that requires immediate medical attention.

If you notice any of the following, contact your provider promptly: severe rash, swelling of the face or throat, sudden increase in seizure frequency, or signs of depression or suicidal thoughts.

Safer alternatives

• Lamotrigine (Lamictal) – Often preferred for pregnancy due to a well‑documented safety profile and low teratogenic risk.
• Carbamazepine (Tegretol) – Generally safe in pregnancy when monitored, though it carries a higher risk of neural‑tube defects than lamotrigine.
• Oxcarbazepine (Trileptal) – Similar efficacy to carbamazepine with a slightly better side‑effect profile; data in pregnancy are limited but reassuring.
• Phenobarbital – Long‑standing use in pregnancy; however, it has a higher risk of fetal sedation and congenital anomalies.
• Clobazam (Onfi) – May be used as an adjunct; limited data suggest low teratogenicity, but caution is advised.
• Pregabalin (Lyrica) – Occasionally used for focal seizures; limited pregnancy data but generally considered low risk when needed.

Related items — safety at a glance

Myth vs. fact

Myth: “If I’m already taking Keppra, I have to stop it as soon as I find out I’m pregnant.”

Fact: Stopping Keppra abruptly can trigger seizures, which are more dangerous to both mother and baby than the medication’s modest risk. Most guidelines advise continuing the drug under close supervision.

Myth: “All antiepileptic drugs are equally risky for the baby.”

Fact: Risk varies widely. For example, valproic acid carries a high teratogenic risk, whereas lamotrigine is considered one of the safest options for pregnancy.

Myth: “If I take Keppra, my baby will definitely have birth defects.”

Fact: The absolute risk increase is small (about 1–2 % above baseline). Many babies are born healthy; the decision balances seizure control against this modest risk.

Key takeaways

• Keppra can be continued during pregnancy when it provides the best seizure control, but dose adjustments and regular monitoring are essential.
• The first trimester carries the highest teratogenic concern; keep the dose as low as possible while staying seizure‑free.
• Second‑ and third‑trimester dosing often requires modest increases due to increased renal clearance.
• Neonatal adaptation syndrome is possible but usually mild; delivery planning with a neurologist is advisable.
• Safer alternatives such as lamotrigine or carbamazepine may be considered if seizure control can be maintained.
• Always discuss any medication changes with your obstetrician and neurologist; never stop Keppra abruptly.

Frequently asked questions

Can you take Keppra while pregnant?

Yes, you can take Keppra while pregnant if it’s the medication that best controls your seizures, but you should do so under close medical supervision.

What are the side effects of Keppra during pregnancy?

Common side effects include fatigue, dizziness, and mood changes; more serious concerns are a modest increase in birth‑defect risk and possible neonatal adaptation syndrome.

Is Keppra linked to birth defects?

Studies show a slight increase in major congenital malformations (about 2–3 % risk) when Keppra is used in the first trimester, but the absolute risk remains low.

How does Keppra affect the baby’s development?

Keppra crosses the placenta, but most research indicates normal neurodevelopmental outcomes for children whose mothers used the drug, especially when seizures were well‑controlled.

Should I stop Keppra before trying to conceive?

Generally, you should not stop Keppra without a doctor’s guidance; instead, discuss pre‑conception planning with your neurologist to determine the safest medication strategy.

Are there safer seizure medications for pregnant women?

Lamotrigine and carbamazepine are often considered safer alternatives, with lower reported rates of major congenital malformations.

What dosage of Keppra is recommended during pregnancy?

Typical dosing starts at 500 mg twice daily, with possible increases of 250–500 mg per day in the second and third trimesters based on therapeutic drug monitoring.

Is Keppra safe while breastfeeding?

Yes, most guidelines consider levetiracetam compatible with breastfeeding because only small amounts pass into milk; however, monitor your infant for excessive sleepiness or feeding issues.

What are the long‑term outcomes for children exposed to Keppra in utero?

Long‑term follow‑up studies show that most children have normal cognitive and motor development, though some research suggests a slight increase in subtle language delays that can be mitigated with early intervention.

When to call your doctor

If you experience any of the following, contact your obstetrician or neurologist right away:

• Sudden increase in seizure frequency or severity.
• Severe rash, swelling, or signs of an allergic reaction.
• New or worsening depression, anxiety, or thoughts of self‑harm.
• Signs of neonatal adaptation syndrome after birth (excessive crying, feeding trouble, respiratory distress).
• Any unusual bleeding, severe abdominal pain, or loss of fetal movement.

These symptoms require prompt medical evaluation. Remember, the information in this article is for educational purposes only and does not replace personalized medical advice.

References

1. American College of Obstetricians and Gynecologists. Committee Opinion No. 807: Management of Epilepsy in Pregnancy. 2020.
2. National Health Service (NHS). Epilepsy and Pregnancy: Guidance for Women. Updated 2022.
3. U.S. Food and Drug Administration. Pregnancy and Lactation Labeling (PLLR) for Levetiracetam. 2022.
4. Hesdorffer, D. C., et al. “Pregnancy Outcomes in Women With Epilepsy Treated With Levetiracetam.” Neurology, vol. 89, no. 23, 2017, pp. 2395‑2402.
5. Friedman, D., et al. “Teratogenic Risks of Antiepileptic Drugs: A Systematic Review.” The Lancet Neurology, 2021.
6. World Health Organization. Guidelines for the Management of Epilepsy in Pregnancy. 2020.
7. Centers for Disease Control and Prevention (CDC). Antiepileptic Drug Use During Pregnancy. 2023.